GlassScriptPhysician profile
David C Ragan
NPI 1568403657
$8,188.59
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,337 · 2020: $746 · 2021: $1,401 · 2022: $2,521 · 2023: $2,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,104 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,104.37 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,559.49 | 2019-2023 | |
| Astellas Pharma US INC | $1,345.24 | 2019-2023 | Xtandi, Myrbetriq |
| Janssen Biotech, INC. | $840.16 | 2019-2023 | Erleada, Akeega |
| Abbvie INC. | $689.91 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $677.12 | 2019-2023 | |
| Amgen INC. | $299.92 | 2019-2023 | Xgeva |
| Allergan, INC. | $288.22 | 2019-2022 | |
| Blue Earth Diagnostics | $231.51 | 2019-2023 | |
| Dendreon Pharmaceuticals LLC | $201.98 | 2019-2023 | Provenge |
| Sumitomo Pharma America, INC. | $191.50 | 2023 | Orgovyx, Gemtesa |
| Progenics Pharmaceuticals, INC. | $190.70 | 2021-2023 | Pylarify |
| Merck Sharp & Dohme LLC | $155.14 | 2022-2023 | Keytruda, Welireg, Lynparza |
| Clarus Therapeutics INC. | $142.68 | 2020-2021 | |
| Endo Pharmaceuticals INC. | $130.98 | 2019-2023 | Xiaflex, Aveed, Edex |
| Astrazeneca Pharmaceuticals LP | $120.02 | 2021-2023 | Lynparza |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ragan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.